Prof. Dr rer. nat. Volker Schirrmacher
Director Científico de Inmunología Tumoral del IOZK
Investigador del cáncer e inmunólogo
El Prof. Dr. rer. nat. Volker Schirrmacher fue nombrado asesor científico y catedrático de inmunología del Centro Alemán de Investigación Oncológica (DKFZ) de Heidelberg en 1976. En 1979 se habilitó en inmunología en Heidelberg y en 1986 se convirtió en catedrático. Dirigió el Departamento de Inmunología Celular del DKFZ hasta su jubilación en 2008.
Desde 2008 es Director Científico de Inmunología Tumoral en el IOZK. Su obra científica incluye casi 400 publicaciones en revistas internacionales.
Fue Presidente de la Sección de Investigación Experimental del Cáncer de la Sociedad Alemana del Cáncer en 1987 y 1988 y Presidente de la Sociedad de Investigación de la Metástasis en 1989/80. En 2003 y 2004 representó a Alemania en la Asociación Europea de Investigación sobre el Cáncer (EACR). De 2009 a 2011, fue Presidente de la Sociedad Europea de Inmunología Aplicada (EGAI).
En 1982 recibió el Premio Aronson y el Premio Meyenburg, y en 1988 el Premio Alemán contra el Cáncer.
Es un pionero internacionalmente reconocido de la inmunoterapia contra el cáncer centrada en los virus oncolíticos. Junto con los científicos y médicos del IOZK, trabaja en la integración sistemática de los nuevos descubrimientos científicos para seguir desarrollando la inmunoterapia del IOZK.
"Se sabe que los virus desencadenan diversas enfermedades. Sin embargo, es menos conocido que ciertos virus se utilizan para tratar el cáncer. Hace más de 100 años, los médicos observaron por primera vez que los pacientes se curaban de su cáncer tras infecciones víricas."
Prof. Dr rer. nat. Volker Schirrmacher
Colección: Contribuciones científicas y publicaciones internacionales de Volker Schirrmacher
Más información sobre este tema:
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
The Complexity of Malignant Glioma Treatment
Entrevista con el Prof. Dr. Volker Schirrmacher en Klassik Radio
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Un análisis de IOZK muestra la buena tolerabilidad de la inmunoterapia con IOZK en el glioma pontino intrínseco difuso (DIPG)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
El Prof. Dr. Volker Schirrmacher publica dos innovadores artículos de revisión sobre inmunoterapia
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
El profesor Volker Schirrmacher, del IOZK de Colonia, inaugurará la conferencia en la Universidad de Kiel con su ponencia sobre la investigación de los virus oncolíticos en el contexto de la inmunoterapia individual contra el cáncer.
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
Revista Internacional de Oncología: "De la quimioterapia a la terapia biológica", Prof. Dr. Volker Schirrmacher
Artículo del IOZK sobre ensayos de tratamiento del glioblastoma en la revista especializada: "Austin Oncology Case Report"
Conferencia IOZK: Electrohipertermia modulada en niños con DIPG, conferencia ESHO, Charité Berlin
Publicación del libro del Prof. Dr. Schirrmacher: Quo vadis cancer therapy
Artículo del IOZK en el International Journal of Molecular Sciences por el Prof. Schirrmacher sobre el papel del virus de la enfermedad de Newcastle en la vacunación contra tumores,
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
Artículo de IOZK del Prof. Schirrmacher en "Deutsche Zeitschrift für Onkologie" sobre los fundamentos de la inmunoterapia
Artículo del IOZK en Austin Oncology Case Reports sobre vacunas contra el cáncer
Artículo del Prof. Schirrmacher en Biomedicines: "Cincuenta años de aplicación clínica del virus de la enfermedad de Newcastle"
Informe del Prof. Dr. Schirrmacher en el International Journal of Oncology sobre los hallazgos de memoria de células T reactivas a tumores en la médula ósea.
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
Caso práctico del IOZK sobre la supervivencia a largo plazo de una paciente con cáncer de mama
Artículo del Prof. Dr. Schirrmacher en el semanario médico vienés "Skriptum".
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
El Prof. Dr. Schirrmacher publica un libro electrónico: Harnessing Oncolytic Virus-mediated Antitumour Immunity (Aprovechamiento de la inmunidad antitumoral mediada por virus oncolíticos).
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
Editorial del Prof. Dr. Volker Schirrmacher sobre el artículo "Immunotherapeutic strategies for the treatment of solid tumours" (Estrategias inmunoterapéuticas para el tratamiento de tumores sólidos)
Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer